Final results from the Phase I study of MetMAb, a monovalent antagonist antibody to the receptor Met, dosed as single agent and in combination with bevacizumab in patients with advanced solid malignancies Other Scholarly Work

cited authors

  • Moss, Rebecca A; Bothos, John G; Patel, Premal H; Peterson, Amy C; Eppler, Steve; Bai, Shuang; Nijem, Ihsan; Desnoyers, Luc; Kaur, Surinder; Zha, Jiping; Yu, Wei; Simpson, Joe; Ratain, Mark J; Tan, Antoinette R; Stein, Mark N; Mehnert, Janice M; Salgia, Ravi

authors

publication date

  • April 15, 2011

published in

keywords

  • Life Sciences & Biomedicine
  • Oncology
  • Science & Technology

WoS ID

  • 000209701404369

Digital Object Identifier (DOI)

volume

  • 71

industry collaboration

  • true